APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Liposomal and Lipid Nanoparticle Drug Delivery Systems

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).

In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.

Selected research

Market Analysis & Forecast

Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Analysis and Forecast 2026-2032

Report ID 174007880229 December 2025201 pages

Choose your research edition.

Industry ResearchLiposomal and Lipid Nanoparticle Drug Delivery Systems Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Liposomal and Lipid Nanoparticle Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

Nanoparticle Drug Delivery Systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.

In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).

Read the full market overview

In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.

Global players of Liposomal and Lipid Nanoparticle Drug Delivery Systems include Gilead Sciences, Pacira, CSPC, Alnylam and Luye Pharma, etc. Top five players occupy for share about 40%. North America is the largest market, with a share over 35%, followed by Europe and Asia-Pacific. In terms of product, Liposomes Drugs is the largest segment, with a share over 90%. In terms of application, Retail Pharmacy is the largest market, followed by Hospital.

Report Includes

This report presents an overview of global market for Liposomal and Lipid Nanoparticle Drug Delivery Systems, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Liposomal and Lipid Nanoparticle Drug Delivery Systems, also provides the revenue of main regions and countries. Of the upcoming market potential for Liposomal and Lipid Nanoparticle Drug Delivery Systems, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Liposomal and Lipid Nanoparticle Drug Delivery Systems revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Liposomal and Lipid Nanoparticle Drug Delivery Systems revenue, projected growth trends, production technology, application and end-user industry.

Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Company

Johnson & Johnson

Sun Pharmaceutical

CSPC

Kinyond

Teva

Fudan-Zhangjiang

Zydus Cadila

TTY Biopharma

Pacira

Luye Pharma

Leadiant Biosciences

Ipsen

Sayre Therapeutics

Jazz

Alnylam

Bausch Health

Acrotech Biopharma

Takeda

Chiesi Farmaceutici

Gilead Sciences

Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Type

Liposomes Drugs

Lipid Nanoparticle Drugs

Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Application

Hospital

Retail Pharmacy

Other

Liposomal and Lipid Nanoparticle Drug Delivery Systems Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal and Lipid Nanoparticle Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liposomal and Lipid Nanoparticle Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal and Lipid Nanoparticle Drug Delivery Systems.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Liposomal and Lipid Nanoparticle Drug Delivery Systems in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Liposomal and Lipid Nanoparticle Drug Delivery Systems company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Liposomal and Lipid Nanoparticle Drug Delivery Systems revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Liposomes Drugs Major Player Table 3. Lipid Nanoparticle Drugs Major Player Table 4. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Retail Pharmacy Major Player Table 7. Other Major Player Table 8. Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Trends Table 9. Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Drivers Table 10. Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Opportunities and Challenges Table 11. Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Restraints Table 12. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2021-2026) Table 15. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region (2027-2032) Table 17. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2021-2026) Table 19. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Headquarters & Area Served Table 21. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Product Type & Application Table 22. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2021-2026) Table 29. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2027-2032) Table 30. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2021-2026) Table 34. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2027-2032) Table 35. Johnson & Johnson Company Information Table 36. Johnson & Johnson Business Overview Table 37. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 39. Johnson & Johnson Recent Development Table 40. Sun Pharmaceutical Company Information Table 41. Sun Pharmaceutical Business Overview Table 42. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 44. Sun Pharmaceutical Recent Development Table 45. CSPC Company Information Table 46. CSPC Business Overview Table 47. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 49. CSPC Recent Development Table 50. Kinyond Company Information Table 51. Kinyond Business Overview Table 52. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 54. Kinyond Recent Development Table 55. Teva Company Information Table 56. Teva Business Overview Table 57. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 59. Teva Recent Development Table 60. Fudan-Zhangjiang Company Information Table 61. Fudan-Zhangjiang Business Overview Table 62. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 64. Fudan-Zhangjiang Recent Development Table 65. Zydus Cadila Company Information Table 66. Zydus Cadila Business Overview Table 67. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 69. Zydus Cadila Recent Development Table 70. TTY Biopharma Company Information Table 71. TTY Biopharma Business Overview Table 72. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 74. TTY Biopharma Recent Development Table 75. Pacira Company Information Table 76. Pacira Business Overview Table 77. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 79. Pacira Recent Development Table 80. Luye Pharma Company Information Table 81. Luye Pharma Business Overview Table 82. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 84. Luye Pharma Recent Development Table 85. Leadiant Biosciences Company Information Table 86. Leadiant Biosciences Business Overview Table 87. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 88. Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 89. Leadiant Biosciences Recent Development Table 90. Ipsen Company Information Table 91. Ipsen Business Overview Table 92. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 93. Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 94. Ipsen Recent Development Table 95. Sayre Therapeutics Company Information Table 96. Sayre Therapeutics Business Overview Table 97. Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 98. Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 99. Sayre Therapeutics Recent Development Table 100. Jazz Company Information Table 101. Jazz Business Overview Table 102. Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 103. Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 104. Jazz Recent Development Table 105. Alnylam Company Information Table 106. Alnylam Business Overview Table 107. Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 108. Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 109. Alnylam Recent Development Table 110. Bausch Health Company Information Table 111. Bausch Health Business Overview Table 112. Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 113. Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 114. Bausch Health Recent Development Table 115. Acrotech Biopharma Company Information Table 116. Acrotech Biopharma Business Overview Table 117. Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 118. Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 119. Acrotech Biopharma Recent Development Table 120. Takeda Company Information Table 121. Takeda Business Overview Table 122. Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 123. Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 124. Takeda Recent Development Table 125. Chiesi Farmaceutici Company Information Table 126. Chiesi Farmaceutici Business Overview Table 127. Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 128. Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 129. Chiesi Farmaceutici Recent Development Table 130. Gilead Sciences Company Information Table 131. Gilead Sciences Business Overview Table 132. Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Sales (Tons), Revenue (US$ Million), Price (USD/Ton) and Gross Margin (2021-2026) Table 133. Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio Table 134. Gilead Sciences Recent Development Table 135. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 136. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 137. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 138. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 139. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 141. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (US$ Million) & (2027-2032) Table 142. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 145. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 146. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 148. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (US$ Million) & (2027-2032) Table 149. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 150. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 151. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 152. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 153. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 154. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 155. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 156. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 157. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 158. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Region (US$ Million) & (2021-2026) Table 159. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Region (US$ Million) & (2027-2032) Table 160. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026) & (US$ Million) Table 161. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032) & (US$ Million) Table 162. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026) & (US$ Million) Table 163. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032) & (US$ Million) Table 164. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 165. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026) & (US$ Million) Table 166. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (US$ Million) & (2027-2032) Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. Liposomal and Lipid Nanoparticle Drug Delivery Systems Image Figure 2. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Share 2021 VS 2025 VS 2032 Figure 4. Liposomes Drugs Image Figure 5. Lipid Nanoparticle Drugs Image Figure 6. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Retail Pharmacy Image Figure 10. Other Image Figure 11. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size (US$ Million) & (2021-2032) Figure 12. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2021-2032) Figure 19. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2021-2032) Figure 22. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032) Figure 24. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032) Figure 25. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Country (2021-2032) Figure 26. United States Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032) Figure 31. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032) Figure 32. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Country (2021-2032) Figure 33. Germany Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032) Figure 43. China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032) Figure 44. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032) Figure 46. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032) Figure 47. Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Region (2021-2032) Figure 48. Japan Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032) Figure 56. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032) Figure 57. SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Country (2021-2032) Figure 58. Brazil Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomes Drugs
  • Lipid Nanoparticle Drugs
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Johnson & Johnson
  • Sun Pharmaceutical
  • CSPC
  • Kinyond
  • Teva
  • Fudan-Zhangjiang
  • Zydus Cadila
  • TTY Biopharma
  • Pacira
  • Luye Pharma
  • Leadiant Biosciences
  • Ipsen
  • Sayre Therapeutics
  • Jazz
  • Alnylam
  • Bausch Health
  • Acrotech Biopharma
  • Takeda
  • Chiesi Farmaceutici
  • Gilead Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market by Type
  3. 1.2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Liposomes Drugs
  5. 1.2.3 Lipid Nanoparticle Drugs
  6. 1.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market by Application
  7. 1.3.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Dynamics
  1. 2.1 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Trends
  2. 2.2 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Drivers
  3. 2.3 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Opportunities and Challenges
  4. 2.4 Liposomal and Lipid Nanoparticle Drug Delivery Systems Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Perspective (2021-2032)
  2. 3.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Growth Trends by Region
  3. 3.2.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2021-2026)
  5. 3.2.3 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Players
  2. 4.1.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Players (2021-2026)
  3. 4.1.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Key Players Headquarters & Area Served
  7. 4.4 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players, Product Type & Application
  8. 4.5 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market CR5 and HHI
  11. 4.6.3 2025 Liposomal and Lipid Nanoparticle Drug Delivery Systems Tier 1, Tier 2, and Tier 3
5 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Type
  1. 5.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 5.3 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Type (2021-2032)
6 Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size by Application
  1. 6.1 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  3. 6.3 Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Sun Pharmaceutical
  8. 7.2.1 Sun Pharmaceutical Company Information
  9. 7.2.2 Sun Pharmaceutical Business Overview
  10. 7.2.3 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sun Pharmaceutical Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  12. 7.2.5 Sun Pharmaceutical Recent Developments
  13. 7.3 CSPC
  14. 7.3.1 CSPC Company Information
  15. 7.3.2 CSPC Business Overview
  16. 7.3.3 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  17. 7.3.4 CSPC Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  18. 7.3.5 CSPC Recent Developments
  19. 7.4 Kinyond
  20. 7.4.1 Kinyond Company Information
  21. 7.4.2 Kinyond Business Overview
  22. 7.4.3 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Kinyond Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  24. 7.4.5 Kinyond Recent Developments
  25. 7.5 Teva
  26. 7.5.1 Teva Company Information
  27. 7.5.2 Teva Business Overview
  28. 7.5.3 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Teva Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  30. 7.5.5 Teva Recent Developments
  31. 7.6 Fudan-Zhangjiang
  32. 7.6.1 Fudan-Zhangjiang Company Information
  33. 7.6.2 Fudan-Zhangjiang Business Overview
  34. 7.6.3 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fudan-Zhangjiang Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  36. 7.6.5 Fudan-Zhangjiang Recent Developments
  37. 7.7 Zydus Cadila
  38. 7.7.1 Zydus Cadila Company Information
  39. 7.7.2 Zydus Cadila Business Overview
  40. 7.7.3 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Zydus Cadila Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  42. 7.7.5 Zydus Cadila Recent Developments
  43. 7.8 TTY Biopharma
  44. 7.8.1 TTY Biopharma Company Information
  45. 7.8.2 TTY Biopharma Business Overview
  46. 7.8.3 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  47. 7.8.4 TTY Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  48. 7.8.5 TTY Biopharma Recent Developments
  49. 7.9 Pacira
  50. 7.9.1 Pacira Company Information
  51. 7.9.2 Pacira Business Overview
  52. 7.9.3 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pacira Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  54. 7.9.5 Pacira Recent Developments
  55. 7.10 Luye Pharma
  56. 7.10.1 Luye Pharma Company Information
  57. 7.10.2 Luye Pharma Business Overview
  58. 7.10.3 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Luye Pharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  60. 7.10.5 Luye Pharma Recent Developments
  61. 7.11 Leadiant Biosciences
  62. 7.11.1 Leadiant Biosciences Company Information
  63. 7.11.2 Leadiant Biosciences Business Overview
  64. 7.11.3 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Leadiant Biosciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  66. 7.11.5 Leadiant Biosciences Recent Developments
  67. 7.12 Ipsen
  68. 7.12.1 Ipsen Company Information
  69. 7.12.2 Ipsen Business Overview
  70. 7.12.3 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Ipsen Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  72. 7.12.5 Ipsen Recent Developments
  73. 7.13 Sayre Therapeutics
  74. 7.13.1 Sayre Therapeutics Company Information
  75. 7.13.2 Sayre Therapeutics Business Overview
  76. 7.13.3 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Sayre Therapeutics Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  78. 7.13.5 Sayre Therapeutics Recent Developments
  79. 7.14 Jazz
  80. 7.14.1 Jazz Company Information
  81. 7.14.2 Jazz Business Overview
  82. 7.14.3 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Jazz Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  84. 7.14.5 Jazz Recent Developments
  85. 7.15 Alnylam
  86. 7.15.1 Alnylam Company Information
  87. 7.15.2 Alnylam Business Overview
  88. 7.15.3 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Alnylam Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  90. 7.15.5 Alnylam Recent Developments
  91. 7.16 Bausch Health
  92. 7.16.1 Bausch Health Company Information
  93. 7.16.2 Bausch Health Business Overview
  94. 7.16.3 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bausch Health Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  96. 7.16.5 Bausch Health Recent Developments
  97. 7.17 Acrotech Biopharma
  98. 7.17.1 Acrotech Biopharma Company Information
  99. 7.17.2 Acrotech Biopharma Business Overview
  100. 7.17.3 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Acrotech Biopharma Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  102. 7.17.5 Acrotech Biopharma Recent Developments
  103. 7.18 Takeda
  104. 7.18.1 Takeda Company Information
  105. 7.18.2 Takeda Business Overview
  106. 7.18.3 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Takeda Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  108. 7.18.5 Takeda Recent Developments
  109. 7.19 Chiesi Farmaceutici
  110. 7.19.1 Chiesi Farmaceutici Company Information
  111. 7.19.2 Chiesi Farmaceutici Business Overview
  112. 7.19.3 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Chiesi Farmaceutici Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  114. 7.19.5 Chiesi Farmaceutici Recent Developments
  115. 7.20 Gilead Sciences
  116. 7.20.1 Gilead Sciences Company Information
  117. 7.20.2 Gilead Sciences Business Overview
  118. 7.20.3 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Gilead Sciences Liposomal and Lipid Nanoparticle Drug Delivery Systems Product Portfolio
  120. 7.20.5 Gilead Sciences Recent Developments
8 North America
  1. 8.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue (2021-2032)
  2. 8.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 8.2.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026)
  4. 8.2.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032)
  5. 8.3 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032)
  6. 8.4 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  7. 8.4.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026)
  8. 8.4.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032)
  9. 8.5 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032)
  10. 8.6 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country
  11. 8.6.1 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026)
  13. 8.6.3 North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue (2021-2032)
  2. 9.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 9.2.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026)
  4. 9.2.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032)
  5. 9.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032)
  6. 9.4 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  7. 9.4.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026)
  8. 9.4.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032)
  9. 9.5 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032)
  10. 9.6 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country
  11. 9.6.1 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026)
  13. 9.6.3 Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue (2021-2032)
  2. 10.2 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 10.2.1 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026)
  4. 10.2.2 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032)
  5. 10.3 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032)
  6. 10.4 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  7. 10.4.1 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026)
  8. 10.4.2 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032)
  9. 10.5 China Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue (2021-2032)
  2. 11.2 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 11.2.1 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026)
  4. 11.2.2 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032)
  5. 11.3 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032)
  6. 11.4 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  7. 11.4.1 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026)
  8. 11.4.2 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032)
  9. 11.5 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032)
  10. 11.6 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country
  11. 11.6.1 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026)
  13. 11.6.3 Asia Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue (2021-2032)
  2. 12.2 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Type (2027-2032)
  5. 12.3 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Application (2027-2032)
  9. 12.5 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country
  11. 12.6.1 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Liposomal and Lipid Nanoparticle Drug Delivery Systems Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst